congenital hypogonadotropic hypogonadism
Conditions
Interventions
Human menopausal gonadotropin pretreatment group:HMG was pretreated for 3 months at a dose of 75 IU q72h im. after which treatment was continued for at least 9 months in combination with hCG 2000 IU q
Human menopausal gonadotropin combined with chorionic gonadotropin group:HMG 75IU + hCG 2000IU q72h im for at least 12 months of continuous treatment.
Sponsors
West China Second University Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
14 Years to 30 Years
Inclusion criteria
Inclusion criteria: Male patients aged 14-30 years diagnosed with CHH, including Kallmann syndrome, CHARGE syndrome, pituitary stalk interruption syndrome (PSIS), and other patients with a diagnosis of CHH after evaluation of hCG provocation test or GnRH provocation test.
Exclusion criteria
Exclusion criteria: Diseases such as constitutional delay of growth and puberty (CDGP), primary hypogonadism, functional hypogonadism, Prader-Willi syndrome, untreated hypothalamic and/or pituitary tumors; patients who took testosterone replacement therapy or testosterone combined with hCG to induce puberty within 6 months; patients who had pulsatile gonadotropin releasing hormone or HMG combined with hCG therapy patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sperm concentration;Total testicular volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum total testosterone;Anti-müllerian hormone (AMH);Inhibin B;Follicle-stimulating hormone (FSH);Luteinizing hormone (LH);Height;Weight;Skeletal age; | — |
Countries
China
Contacts
Public ContactXiao-hui Jiang
West China Second University Hospital of Sichuan University
Outcome results
None listed